Cancer Research Technology
Log in Register
Menu

Anti-S100A8 & S100A9, Recombinant [5.5]

Invented at Cancer Research UK London Research Institute: Lincoln's Inn Fields

Info

Catalogue Number 153260
Applications ELISA FACS IHC IP WB
Antigen/Gene or Protein Targets S100A8 (MRP-8) & S100A9 (MRP-14)
Reactivity Human
Relevance S100A8 (MRP-8) and S100A9 (MRP-14) are cytosolic calcium-binding proteins of 8kDa and 14kDa that form a heterodimer. S100A8 and S100A9 are expressed in secretory and inflamed keratinocytes, peripheral blood monocytes, neutrophils and has been described in platelets, dendritic cells and some T cell types. Expression is lost on tissue maturation of monocytes to macrophages. S100A9 may be associated with monocyte and neutrophil activation and the accumulation of these cells in inflammatory sites.
Host Mouse
Immunogen Acute monocytic leukaemia cells.
Subclass IgG1
Formulation PBS
Concentration 1mgml-1
Research Area Cell Signaling & Signal Transduction, Immunology
Notes Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.

Five products based on this clone:
- Anti-S100A8 & S100A9 [5.5], Mouse IgG1, Kappa
- Anti-S100A8 & S100A9 [5.5], Rabbit IgG, Kappa
- Anti-S100A8 & S100A9 [5.5], Human IgG4-S228P, Kappa
- Anti-S100A8 & S100A9 [5.5], Human IgG1, Kappa
- Anti-S100A8 & S100A9 [5.5], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Original hybridoma first published in: Hogg et al. 1989. Eur J Immunol. 19(6):1053-61. PMID: 2666142.


Add a reference

References: 1 entry

Original hybridoma first published in: Hogg et al. 1989. Eur J Immunol. 19(6):1053-61. PMID: 2666142.


Add a reference

Inventor Information